Colibri Heart Valve

Executive Summary

Colibri Heart Valve is a privately held medical device company headquartered in Boulder, Colorado, focused on developing innovative transcatheter heart valve replacement solutions. Founded in 2006, the company has been refining its proprietary valve technology to address the limitations of current surgical and transcatheter approaches, particularly in the treatment of aortic stenosis. While specific financial and clinical data remain undisclosed, the company's long history in the cardiovascular space suggests a deep commitment to bringing a differentiated product to market. The device likely emphasizes durability, ease of delivery, and reduced procedural complications, which could position Colibri as a competitor in the rapidly growing TAVR market, projected to exceed $10 billion by 2030. The company's lack of public funding rounds or partnership announcements may indicate a bootstrapped or strategic approach, with potential reliance on internal resources or undisclosed investors. As Colibri moves toward commercialization, key milestones will include regulatory engagements in the US and Europe, a pivotal clinical trial, and securing manufacturing scale-up. With the TAVR field dominated by Edwards Lifesciences and Medtronic, Colibri will need to demonstrate clear clinical advantages to capture market share. The company's future prospects hinge on successful trial outcomes and strategic partnerships to navigate the complex regulatory and reimbursement landscape.

Upcoming Catalysts (preview)

• Q2 2027Completion of Pivotal US IDE Trial Enrollment65% success
• Q4 2026FDA Pre-Submission or Q-Sub Meeting70% success